190 related articles for article (PubMed ID: 1898893)
1. The role of endogenous gonadotropin release in the etiology of ovarian enlargement during purified urinary follicle-stimulating hormone therapy.
Mizunuma H; Takagi T; Yamada K; Andoh K; Ibuki Y; Igarashi M
Fertil Steril; 1991 Jan; 55(1):66-72. PubMed ID: 1898893
[TBL] [Abstract][Full Text] [Related]
2. Oestradiol and immunoreactive inhibin-like secretory patterns following controlled ovarian hyperstimulation with urinary (Metrodin) or recombinant follicle stimulating hormone (Puregon).
Mitchell R; Buckler HM; Matson P; Lieberman B; Burger HG; Hilton B; Horne G; Dyson M; Robertson WR
Hum Reprod; 1996 May; 11(5):962-7. PubMed ID: 8671371
[TBL] [Abstract][Full Text] [Related]
3. Induction of ovulation in polycystic ovary: human menopausal gonadotropin or human urinary follicle stimulating hormone?
Venturoli S; Paradisi R; Fabbri R; Porcu E; Orsini LF; Flamigni C
Int J Fertil; 1987; 32(1):66-70. PubMed ID: 2880819
[TBL] [Abstract][Full Text] [Related]
4. Successful induction of ovulation and conception with combined gonadotropin-releasing hormone agonist plus highly purified follicle-stimulating hormone in patients with polycystic ovarian disease.
Lanzone A; Fulghesu AM; Spina MA; Apa R; Menini E; Caruso A; Mancuso S
J Clin Endocrinol Metab; 1987 Dec; 65(6):1253-8. PubMed ID: 3119655
[TBL] [Abstract][Full Text] [Related]
5. Ovulation induction with low doses of "pure" follicle stimulating hormone using a fixed protocol in patients with polycystic ovarian disease.
Bregieiro LO; de Moura MD; Ferriani RA; Bailão LA; de Sá MF
Int J Fertil Menopausal Stud; 1993; 38(3):152-9. PubMed ID: 8348163
[TBL] [Abstract][Full Text] [Related]
6. Comparison of urinary human follicle-stimulating hormone and human menopausal gonadotropin for ovarian stimulation in polycystic ovarian syndrome.
Larsen T; Larsen JF; Schiøler V; Bostofte E; Felding C
Fertil Steril; 1990 Mar; 53(3):426-31. PubMed ID: 2106449
[TBL] [Abstract][Full Text] [Related]
7. Ovarian luteinizing hormone priming preceding follicle-stimulating hormone stimulation: clinical and endocrine effects in women with long-term hypogonadotropic hypogonadism.
Balasch J; Fábregues F; Carmona F; Casamitjana R; Tena-Sempere M
J Clin Endocrinol Metab; 2009 Jul; 94(7):2367-73. PubMed ID: 19366842
[TBL] [Abstract][Full Text] [Related]
8. Early prediction of ovarian multifollicular response during ovulation induction in patients with polycystic ovary syndrome.
Farhi J; Jacobs HS
Fertil Steril; 1997 Mar; 67(3):459-62. PubMed ID: 9091330
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of ovarian follicular maturation with pure follicle-stimulating hormone in women with gonadotropin deficiency.
Couzinet B; Lestrat N; Brailly S; Forest M; Schaison G
J Clin Endocrinol Metab; 1988 Mar; 66(3):552-6. PubMed ID: 3127417
[TBL] [Abstract][Full Text] [Related]
10. Prediction and prevention of ovarian hyperstimulation by monitoring endogenous luteinizing hormone release during purified follicle-stimulating hormone therapy.
Mizunuma H; Andoh K; Yamada K; Takagi T; Kamijo T; Ibuki Y
Fertil Steril; 1992 Jul; 58(1):46-50. PubMed ID: 1624022
[TBL] [Abstract][Full Text] [Related]
11. [Clinical significance of counting follicles in diagnosis of polycystic ovary syndrome by the three-dimensional ultrasound imaging with sonography based automated volume calculation method].
He LR; Zhou LX; Pan RK; Zhang X
Zhonghua Fu Chan Ke Za Zhi; 2011 May; 46(5):350-4. PubMed ID: 21733371
[TBL] [Abstract][Full Text] [Related]
12. Blood flow changes in the ovarian and uterine arteries in women with polycystic ovary syndrome who respond to clomiphene citrate: correlation with serum hormone concentrations.
Zaidi J; Jacobs H; Campbell S; Tan SL
Ultrasound Obstet Gynecol; 1998 Sep; 12(3):188-96. PubMed ID: 9793191
[TBL] [Abstract][Full Text] [Related]
13. Ovulation induction in clomiphene-resistant anovulatory women: differential follicular response to purified urinary follicle-stimulating hormone (FSH) versus purified urinary FSH and luteinizing hormone.
Hoffman DI; Lobo RA; Campeau JD; Tsai HM; Holmberg EA; Ono T; Frederick JJ; Platt LD; diZerega GS
J Clin Endocrinol Metab; 1985 May; 60(5):922-7. PubMed ID: 3920235
[TBL] [Abstract][Full Text] [Related]
14. Importance of echographic and endocrine monitoring for the assessment of ovulation by follicle stimulating hormone in polycystic ovarian disease.
Caruso A; Lanzone A; Fulghesu AM; Apa R; Guida C; Mancuso S
Int J Gynaecol Obstet; 1989 Feb; 28(2):163-9. PubMed ID: 2563704
[TBL] [Abstract][Full Text] [Related]
15. Luteinizing hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome.
Filicori M; Cognigni GE; Taraborrelli S; Spettoli D; Ciampaglia W; de Fatis CT; Pocognoli P
J Clin Endocrinol Metab; 1999 Aug; 84(8):2659-63. PubMed ID: 10443656
[TBL] [Abstract][Full Text] [Related]
16. Stimulation and growth of antral ovarian follicles by selective LH activity administration in women.
Filicori M; Cognigni GE; Tabarelli C; Pocognoli P; Taraborrelli S; Spettoli D; Ciampaglia W
J Clin Endocrinol Metab; 2002 Mar; 87(3):1156-61. PubMed ID: 11889180
[TBL] [Abstract][Full Text] [Related]
17. [Effects of gonadotropin releasing hormone analogues on chemotherapy-induced ovarian function damage in rats].
Peng P; Yang DZ; Zheng CY; Mo YQ; He YM; Zhang QX
Zhonghua Fu Chan Ke Za Zhi; 2007 Aug; 42(8):546-50. PubMed ID: 17983495
[TBL] [Abstract][Full Text] [Related]
18. [Hormone profile and follicle development in ovarian stimulation treatment for in vitro fertilization. 1. FSH and LH profiles].
Sudik R; Fliess FR; Kunkel S
Zentralbl Gynakol; 1987; 109(24):1478-92. PubMed ID: 3126616
[TBL] [Abstract][Full Text] [Related]
19. Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy: a possible mechanism regulating emergence of the dominant follicle.
Lockwood GM; Muttukrishna S; Groome NP; Matthews DR; Ledger WL
J Clin Endocrinol Metab; 1998 May; 83(5):1730-5. PubMed ID: 9589683
[TBL] [Abstract][Full Text] [Related]
20. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
